Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
The company said the sale includes 1,647,447 shares and warrants for up to 3,294,894 more shares, with gross proceeds of about $3.0 million.
- On Tuesday, Co-Diagnostics announced a private placement to raise approximately $3.0 million, selling 1,647,447 shares of common stock and warrants to institutional investors under Nasdaq rules.
- Maxim Group LLC serves as sole placement agent, with a combined effective offering price of $1.821 per share and warrant; warrants carry an exercise price of $1.571 per share, exercisable immediately and expiring five years from issuance.
- Expected to close on Thursday, May 21, 2026, the offering follows a private placement structure under Section 4 of the Securities Act of 1933; the Company agreed to file a registration statement with the SEC.
- Co-Diagnostics, a Utah corporation, develops molecular diagnostic tests using proprietary technology for its Co-Dx PCR at-home and point-of-care platform, subject to regulatory review.
- Risks to the Offering include satisfaction of customary closing conditions and timing of SEC filing effectiveness; forward-looking statements are based on current expectations and subject to material risks.
30 Articles
30 Articles
What's Going On With Co-Diagnostics Stock Wednesday? - Co-Diagnostics (NASDAQ:CODX)
Co-Diagnostics, Inc. (NASDAQ:CODX) stock is trading higher on Wednesday as the company announced a private placement aimed at raising approximately $3.0 million. Co-Diagnostics Private Placement Details The molecular diagnostics company plans to sell an aggregate of 1,647,447 shares along with warrants to purchase up to 3,294,894 shares. The effective offering price for each share and accompanying warrants is set at $1.821. On Tuesday, Co-Diagno…
ABC FOX Montana
Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx", or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into a…
Co-Diagnostics Jumps; $3 Million Deal Looms
Co-Diagnostics announced a $3 million private placement after its stock surged 43.8% Tuesday, then fell 13.3% in after-hours trading. The company will sell 1.65 million shares or pre-funded warrants, plus warrants for up to 3.29 million more shares, nearly doubling its share count. The move follows its completion of a Bundibugyo virus assay as Ebola spreads in Congo and Uganda. Co-Diagnostics reported $8.2 million in cash at March 31. The post C…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
